在老年人中,G蛋白结合雌激素受体1,粉样蛋白-β和纠
Shahram Oveisgharan1,2, Lei Yu3,4, Katia de Paiva Lopes3,4
1Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA. shahram_oveisgharan@rush.edu.
Communications biology
|May 15, 2024
概括
在阿尔茨海默病中,GPER1基因可能会将粉样β (Aβ) 和团联系起来. 天体细胞GPER1的表达影响了Aβ积累与tau病理的关系,这表明了潜在的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 阿尔茨海默氏病 (AD) 的特征是细胞外粉样β (Aβ) 斑块和细胞内团.
- Aβ和tau蛋白质病变之间的确切关系尚不清楚.
- 调查这些特征之间的分子联系对于理解AD病变的产生至关重要.
研究的目的:
- 调查G蛋白结合雌激素受体1 (GPER1) RNA表达在修改AD中Aβ和tau纠结之间的关联中的作用.
- 确定GPER1表达影响这种关系的特定细胞类型.
主要方法:
- 分析了1206名老年人的RNA表达数据.
- 在GPER1RNA水平,Aβ负载 (免疫组织化学) 和陶病理学之间的相关性分析.
- 单核RNA测序 (snRNA-seq) 用于检查不同类型的大脑细胞 (星细胞,神经元,内皮细胞) 中的GPER1表达.
主要成果:
- GPER1 RNA表达显著与增加的陶纠相关 (p=0.001).
- GPER1表达调节了Aβ负载和tau纠结之间的关联 (p=0.044).
- 对总Aβ蛋白 (p=0.030) 和Aβ38 (p=0.002) 观察到这种调制.
- snRNA-seq揭示了天体细胞GPER1RNA表达,但不是在神经元或内皮细胞中,显著改变了Aβ-tau关系 (p=0.002).
结论:
- 在阿尔茨海默病中,GPER1可能作为连接Aβ积累和陶形成的分子环节.
- 天体细胞GPER1表达似乎是这种Aβ-tau相互作用的关键驱动因素.
- 向天体细胞GPER1可能是AD的新治疗策略.
相关概念视频
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Enzyme-linked Receptors
78.2K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.2K


